Pfizer Inc
NYSE: PFE
$25.72
+$0.12 (+0.5%)
Closing Price on March 14, 2025
PFE Articles
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
As of the most recently reported settlement date, short sellers still favored Microsoft, Intel and Pfizer above all other Dow stocks.
Published:
With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the Dow are still holding the index back from even stronger gains.
Published:
Shares of Merck and Pfizer both got boosts after they reported their most recent quarterly results before the opening bell Tuesday.
Published:
Merck and Pfizer are set to report their most recent quarterly results before the opening bell tomorrow. Pfizer is one of the most shorted of all Dow stocks.
Published:
Six of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Published:
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
As of the most recently reported period, short sellers still favored Microsoft, Intel and Pfizer above all other Dow stocks.
Published:
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Published:
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
Published:
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
As of the most recently reported period, short sellers favored Microsoft, Intel and Pfizer above all other Dow stocks.
Published:
The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid long-term prospects.
Published:
Pfizer has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
Published:
The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.